Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage

Vaccine

Volumn 28, Issue 48, 2010, Pages 7667-7675

  Ala'Aldeen, Dlawer A A ^a   Flint, Mike ^b   Oldfield, Neil J ^a   Omer, Sherko A ^a   McNeil, Lisa K ^b   Jiang, Qin ^b   Murphy, Ellen ^b   Giardina, Peter C ^b   Novikova, Elena G ^b   Dodge Scully, Ingrid L ^b   Bayliss, Christopher D ^c   Turner, David P J ^a   Neal, Keith R ^a   Hoiseth, Susan K ^b   Jansen, Kathrin U ^b   Anderson, Annaliesa S ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b PFIZER INC   (United States)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Factor H binding protein; LP2086; Neisseria meningitidis

Indexed keywords

BACTERIAL PROTEIN; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; CLINICAL ARTICLE; HOSPITAL ADMISSION; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CARRIER STATE; FEMALE; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; NEISSERIA MENINGITIDIS, SEROGROUP B; RABBITS; YOUNG ADULT;

EID: 78249263206     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.038     Document Type: Article

References (32)

1. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369(9580):2196-2210.
2. Caugant D.A., Maiden M.C. Meningococcal carriage and disease-population biology and evolution. Vaccine 2009, 27(Suppl 2):B64-B70.
3. Yazdankhah S.P., Caugant D.A. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004, 53(Pt 9):821-832.
4. Caugant D.A., Tzanakaki G., Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev 2007, 31(1):52-63.
5. Jolley K.A., Gray S.J., Suker J., Urwin R. Methods for typing of meningococci. Handbook of meningococcal disease infection biology, vaccination, clinical management 2006, Wiley-VCH, Weinheim, Germany. M. Frosch, M.C.J. Maiden (Eds.).
6. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 2005, 23(17-18):2222-2227.
7. Pollard A.J., Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine 2001, 19(11-12):1327-1346.
8. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129(6):1307-1326.
9. Bruge J., Bouveret-Le Cam N., Danve B., Rougon G., Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004, 22(9-10):1087-1096.
10. Granoff D.M. Review of meningococcal group b vaccines. Clin Infect Dis 2010, 50(S2):S54-S65.
11. Sadarangani M., Pollard A.J., Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010, 10(2):112-124.
12. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177(1):501-510.
13. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(4):2088-2100.
14. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197(6):789-799.
15. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006, 176(12):7566-7575.
16. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200(3):379-389.
17. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103(29):10834-10839.
18. Marshall H, Nissen MD, Richmond P, Lambert SB, Roberton DM, Jones T, et al. A randomized, placebo-controlled, double-blind, phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults. 16th International Pathogenic Neisseria Conference; 2008; Rotterdam, The Netherlands; 2008.
19. Richmond P, Marshall H, Nissen MD, Lambert S, Jones T, Gruber W, et al. A randomized, observer-blinded, active control, phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years. 16th International Pathogenic Neisseria Conference; 2008; Rotterdam, The Netherlands; 2008.
20. Ala'Aldeen D.A., Neal K.R., Ait-Tahar K., Nguyen-Van-Tam J.S., English A., Falla T.J., et al. Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination. J Clin Microbiol 2000, 38(6):2311-2316.
21. Neal K.R., Nguyen-Van-Tam J.S., Jeffrey N., Slack R.C., Madeley R.J., Ait-Tahar K., et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ 2000, 320(7238):846-849.
22. Taha M.K., Alonso J.M., Cafferkey M., Caugant D.A., Clarke S.C., Diggle M.A., et al. Interlaboratory comparison of PCR-based identification and genogrouping of Neisseria meningitidis. J Clin Microbiol 2005, 43(1):144-149.
23. McNeil L.K., Murphy E., Zhao X.J., Guttmann S., Harris S.L., Scott A.A., et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009, 27(25-26):3417-3421.
24. Jolley K.A., Chan M.S. Maiden MC. mlstdbNet - distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics 2004, 5:86.
25. Jones G.R., Christodoulides M., Brooks J.L., Miller A.R., Cartwright K.A., Heckels J.E. Dynamics of carriage of Neisseria meningitidis in a group of military recruits: subtype stability and specificity of the immune response following colonization. J Infect Dis 1998, 178(2):451-459.
26. Jordens J.Z., Williams J.N., Jones G.R., Christodoulides M., Heckels J.E. Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students. Infect Immun 2004, 72(11):6503-6510.
27. Williams J.N., Skipp P.J., O'Connor C.D., Christodoulides M., Heckels J.E. Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect Immun 2009, 77(11):5080-5089.
28. Jacobsson S., Molling P., Olcen P. Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis. Vaccine 2009, 27(42):5755-5759.
29. Litt D.J., Savino S., Beddek A., Comanducci M., Sandiford C., Stevens J., et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 2004, 190(8):1488-1497.
30. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28(37):6086-6093.
31. Mascioni A., Bentley B.E., Camarda R., Dilts D.A., Fink P., Gusarova V., et al. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J Biol Chem 2009, 284(13):8738-8746.
32. Kindt T.J., Osborne B.A., Goldsby R.A. Kuby immunology 2006, W.H. Freeman. 6th ed.